Results 201 to 210 of about 7,728 (235)

Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study

EClinicalMedicine, 2023
Howard Sofen
exaly  

Prurigo

Archives de Pédiatrie, 2003
openaire   +2 more sources

Single-cell RNA sequencing defines disease-specific differences between chronic nodular prurigo and atopic dermatitis

Journal of Allergy and Clinical Immunology, 2023
Patrick M Brunner
exaly  

[Prurigo].

Presse medicale (Paris, France : 1983), 2009
Prurigo is a medical term which includes several clinical, pathological and etiologic entities. Diagnostic and therapeutic management is different depending on if we face acute prurigo or chronic prurigo. Acute prurigo is almost always linked to parasites or insects.
Annabel, Maruani, Mahtab, Samimi, Gérard, Lorette   +2 more
openaire   +1 more source

Immunotargets and Therapy for Prurigo Nodularis

ImmunoTargets and Therapy, 2022
Teresa Ju, Gil Yosipovitch
exaly  

Prurigo pigmentosa

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2011
Rok, Kokol, Jovan, Miljković, Laila, El Shabrawi-Caelen   +2 more
openaire   +2 more sources

Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis

Expert Review of Clinical Pharmacology, 2021
Youkyung S Roh, Isabelle D Brown, Nishadh Sutaria   +2 more
exaly  

Prurigo Nodularis

Proceedings of the Royal Society of Medicine, 1934
J E, Wigley, G, Heggs
openaire   +2 more sources

Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis

New England Journal of Medicine, 2020
Sonja Ständer, Gil Yosipovitch, Jean-Philippe Lacour   +2 more
exaly  

Prurigo Pigmentosa

The American Journal of Medicine, 2018
Daisuke Yamada, Tatsuya Fujikawa
openaire   +2 more sources